Chinese Journal of Dermatology ›› 2021, Vol. 54 ›› Issue (6): 542-545.doi: 10.35541/cjd.20210037
• Reviews • Previous Articles Next Articles
Luo Shuaihantian1, Long Hai1, Lu Qianjin1,2
Received:2021-01-14
Revised:2021-02-21
Online:2021-06-15
Published:2021-05-31
Contact:
Lu Qianjin
E-mail:qianlu5860@gmail.com
Supported by:Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2020[J]. Chinese Journal of Dermatology, 2021, 54(6): 542-545.doi:10.35541/cjd.20210037
| ［1］ | 罗帅寒天, 龙海, 陆前进. 2018年系统性红斑狼疮研究新进展［J］. 中华皮肤科杂志, 2020,53（8）:665⁃667. doi: 10.35541/cjd. 20190298. |
| ［2］ | 陆前进, 罗帅寒天. 系统性红斑狼疮的诊疗进展［J］. 中华皮肤科杂志, 2018,51（1）:1⁃4. doi: 10.3760/cma.j.issn.0412⁃4030. 2018.01.001. |
| ［3］ | Kazimierczyk M, Kasprowicz MK, Kasprzyk ME, et al. Human long noncoding RNAinteractome: detection, characterization and function［J］. Int J MolSci, 2020,21（3）:1027. doi: 10.3390/ijms21031027. |
| ［4］ | Moore JB 4th, Uchida S. Functional characterization of long noncoding RNAs［J］. CurrOpinCardiol, 2020,35（3）:199⁃206. doi: 10.1097/HCO.0000000000000725. |
| ［5］ | Fan Z, Chen X, Liu L, et al. Association of the polymorphism rs13259960 in SLEAR with predisposition to systemic lupus erythematosus［J］. Arthritis Rheumatol, 2020,72（6）:985⁃996. doi: 10.1002/art.41200. |
| ［6］ | Löfgren SE, Frostegård J, Truedsson L, et al. Genetic association of miRNA⁃146a with systemic lupus erythematosus in Europeans through decreased expression of the gene［J］. Genes Immun, 2012,13（3）:268⁃274. doi: 10.1038/gene.2011.84. |
| ［7］ | Hou G, Harley I, Lu X, et al. SLE non⁃coding genetic risk variant determines the epigenetic dysfunction of an immune cell specific enhancer that controls disease⁃critical microRNA expression［J］. Nat Commun, 2021,12（1）:135. doi: 10.1038/s41467⁃020⁃20460⁃1. |
| ［8］ | Kuo CF, Grainge MJ, Valdes AM, et al. Familial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families［J］. JAMA Intern Med, 2015,175（9）:1518⁃1526. doi: 10.1001/jamainternmed.2015.3528. |
| ［9］ | Wang YF, Zhang Y, Lin Z, et al. Identification of 38 novel loci for systemic lupus erythematosus and genetic heterogeneity between ancestral groups［J］. Nat Commun, 2021,12（1）:772. doi: 10.1038/s41467⁃021⁃21049⁃y. |
| ［10］ | Lee JY, Park JK, Lee EY, et al. Circulating exosomes from patients with systemic lupus erythematosus induce an proinflammatory immune response［J］. Arthritis Res Ther, 2016,18（1）:264. doi: 10.1186/s13075⁃016⁃1159⁃y. |
| ［11］ | 张淑娟, 唐亚萍, 梁景耀, 等. 姜黄素逆转系统性红斑狼疮患者外泌体诱导的巨噬细胞吞噬功能受损［J］. 中华皮肤科杂志, 2019,52（6）:378⁃382. doi: 10.3760/cma.j.issn.0412⁃4030. 2019.06.002. |
| ［12］ | Tsokos GC, Lo MS, Costa Reis P, et al. New insights into the immunopathogenesis of systemic lupus erythematosus［J］. Nat Rev Rheumatol, 2016,12（12）:716⁃730. doi: 10.1038/nrrheum. 2016.186. |
| ［13］ | Lee WS, Amengual O. B cells targeting therapy in the management of systemic lupus erythematosus［J］. Immunol Med, 2020,43（1）:16⁃35. doi: 10.1080/25785826.2019.1698929. |
| ［14］ | Salazar⁃Camarena DC, Palafox⁃Sánchez CA, Cruz A, et al. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients［J］. Sci Rep, 2020,10（1）:6236. doi: 10.1038/s41598⁃020⁃63390⁃0. |
| ［15］ | Skytthe MK, Graversen JH, Moestrup SK. Targeting of CD163（+） macrophages in inflammatory and malignant diseases［J］. Int J MolSci, 2020,21（15）:5497. doi: 10.3390/ijms21155497. |
| ［16］ | Li J, Yu YF, Liu CH, et al. Significance of M2 macrophages in glomerulonephritis with crescents［J］. Pathol Res Pract, 2017,213（9）:1215⁃1220. doi: 10.1016/j.prp.2017.04.011. |
| ［17］ | Li J, Liu CH, Xu DL, et al. Significance of CD163⁃Positive macrophages in proliferative glomerulonephritis［J］. Am J Med Sci, 2015,350（5）:387⁃392. doi: 10.1097/MAJ.0000000000000569. |
| ［18］ | Mejia⁃Vilet JM, Zhang XL, Cruz C, et al. Urinary soluble CD163: a novel noninvasive biomarker of activity for lupus nephritis［J］. J Am Soc Nephrol, 2020,31（6）:1335⁃1347. doi: 10.1681/ASN. 2019121285. |
| ［19］ | You L, Wu W, Wang X, et al. The role of hypoxia⁃inducible factor 1 in tumor immune evasion［J］. Med Res Rev, 2021, 41（3）:1622⁃1643. doi: 10.1002/med.21771. |
| ［20］ | Deng W, Ren Y, Feng X, et al. Hypoxia inducible factor⁃1 alpha promotes mesangial cell proliferation in lupus nephritis［J］. Am J Nephrol, 2014,40（6）:507⁃515. doi: 10.1159/000369564. |
| ［21］ | Ma Z, Xiang X, Li S, et al. Targeting hypoxia⁃inducible factor⁃1, for cancer treatment: recent advances in developing small⁃molecule inhibitors from natural compounds［J］. Semin Cancer Biol, 2020［2020⁃09⁃30］. doi: 10.1016/j.semcancer.2020.09.011. |
| ［22］ | Chen PM, Wilson PC, Shyer JA, et al. Kidney tissue hypoxia dictates T cell⁃mediated injury in murine lupus nephritis［J］. Sci Transl Med, 2020,12（538）:eaay1620. doi: 10.1126/scitranslmed.aay1620. |
| ［23］ | Hogan KA, Chini C, Chini EN. The multi⁃faceted ecto⁃enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases［J］. Front Immunol, 2019,10:1187. doi: 10.3389/fimmu. 2019.01187. |
| ［24］ | Ostendorf L, Burns M, Durek P, et al. Targeting CD38 withdaratumumab in refractory systemic lupus erythematosus［J］. N Engl J Med, 2020,383（12）:1149⁃1155. doi: 10.1056/NEJMoa2023325. |
| ［25］ | 国家食品药品监督管理局. 2020年12月07日药品批准证明文件待领取信息发布［EB/OL］. （2020⁃12⁃07）［2020⁃12⁃08］. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20201207163 143123.html. |
| ［26］ | Dimelow R, Ji B, Struemper H. Pharmacokinetics of belimumab in children with systemic lupus erythematosus［J］. Clin Pharmacol Drug Dev, 2020［2020⁃11⁃30］. doi: 10.1002/cpdd.889. |
| ［27］ | Collins CE, Cortes⁃Hernández J, Garcia MA, et al. Real⁃world effectiveness of belimumab in the treatment of systemic lupus erythematosus: pooled analysis of multi⁃country data from the OBSErve studies ［J］. RheumatolTher, 2020,7（4）:949⁃965. doi: 10.1007/s40744⁃020⁃00243⁃2. |
| ［28］ | Bell CF, Priest J, Stott⁃Miller M, et al. Real⁃world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA［J］. Lupus Sci Med, 2020,7（1）:e000357. doi: 10.1136/lupus⁃2019⁃000357. |
| [1] | Zhang Ning, Li Shu, Li Jing . Efficacy of immune checkpoint inhibitors and targeted therapy in adjuvant treatment of resectable melanoma: a network meta-analysis [J]. Chinese Journal of Dermatology, 2022, 0(4): 20200767-e20200767. |
| [2] | Wang Xiaowen, Li Ruoyu. Superficial fungal infections in psoriasis patients treated with IL-17 related biological agents and their management [J]. Chinese Journal of Dermatology, 2022, 55(3): 272-275. |
| [3] | Lyu Ling, Lyu Xiaoyan. Dermatomyositis with malignancy: an update [J]. Chinese Journal of Dermatology, 2022, 55(3): 276-279. |
| [4] | Li Suo, Xiang Ruiyu, Li Zhiliang, Jing Ke, Wang Yuan, Zhang Hanmei, Feng Suying. Evaluation of the value of indirect immunofluorescence on salt-split skin in the diagnosis of bullous pemphigoid [J]. Chinese Journal of Dermatology, 2022, 55(3): 235-237. |
| [5] | Liu Yuzhen, Zeng Rong, Zheng Nana, Duan Zhimin, Xu Haoxiang, Wu Qiuju, Lin Tong, Li Min. Effect of different incubation time of aminolevulinic acid on photodynamic inhibition of Propionibacterium acnes biofilms [J]. Chinese Journal of Dermatology, 2022, 55(3): 208-212. |
| [6] | Writing committee expert group on “diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2022） [J]. Chinese Journal of Dermatology, 2022, 55(3): 187-195. |
| [7] | Zhang Tingting, Zhu Fengyi, Yang Mei, Zhang Ping, Xia Ping, Zhou Xiaoyong. Clinical efficacy and safety of secukinumab in the treatment of 7 cases of erythrodermic psoriasis [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210644-e20210644. |
| [8] | Wen Guangdong, Mao Dandan, Zhang Yuanyuan, Dou Yuanqing, Zhao Pei, Wu Chenyu, Zhang Jianzhong. A case of generalized lichen amyloidosis treated with dupilumab: the first case reported in China [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210694-e20210694. |
| [9] | Ou Min, Yan Yunling, Zheng Baoqing, Wang Xiaohua. Correlations between psoriasis and obesity [J]. Chinese Journal of Dermatology, 2022, 55(2): 181-184. |
| [10] | Bao Shijie, Cheng Yang, Yan Ying, Fan Fang, Gao Tingting, Feng Xiaolan, Zheng Liang, Lei Wei, Huang Qinsi, Zhang Weiming, Zhou Xiaoyong. A comparative study of human immunoglobulin versus recombinant human tumor necrosis factor-α receptor Ⅱ:IgG Fc fusion protein in the treatment of toxic epidermal necrolysis [J]. Chinese Journal of Dermatology, 2022, 55(2): 153-156. |
| [11] | Jiao Xiaoyan, Yin Guangwen, Yin Yakun, Li Dongqin. Clinical analysis of 25 cases of herpes zoster during pregnancy or the perinatal period [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210384-e20210384. |
| [12] | Li Sai, Xue Huazhong, Zhang Shuwen, Jiang Juan, Qi Shuzhen, Zhao Yuanyuan, Zhang Jinping, Sha Zhong, Le Wenjing, Wang Biwei, Zhao Shixuan, Zhu Xiaofeng, Su Xiaohong. Doxycycline-moxifloxacin sequential therapy for Mycoplasma genitalium urethritis/cervicitis: a clinical observation [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210631-e20210631. |
| [13] | Cheng Bihong, Dou Xia. Diagnosis and classification of chronic prurigo [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210130-e20210130. |
| [14] | Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210420-e20210420. |
| [15] | Luan Chao, Hu Yu, Chen Kun, Zhang Jiaan, Gu Heng, Zhang Ronglin, Zhang Xiaohua, Tian Panpan, Zhu Yan, Zhuang Chen, Huang Dan, Ju Mei. Efficacy and safety of 308-nm SQ light-emitting diode light and 308-nm excimer light in the treatment of facial vitiligo: a retrospective study [J]. Chinese Journal of Dermatology, 2022, 55(1): 16-19. |
|
